The chaperone protein HSP47: a platelet collagen binding protein that contributes to thrombosis and hemostasis. by Sasikumar, P et al.
Sasikumar, P and AlOuda, KS and Kaiser, WJ and Holbrook, LM and Kriek,
N and Unsworth, AJ and Bye, AP and Sage, T and Ushioda, R and Nagata, K
and Farndale, RW and Gibbins, JM (2018)The chaperone protein HSP47: a
platelet collagen binding protein that contributes to thrombosis and hemosta-
sis. Journal of Thrombosis and Haemostasis (JTH), 16 (5). pp. 946-959.
ISSN 1538-7836
Downloaded from: http://e-space.mmu.ac.uk/622745/
Version: Published Version
Publisher: Wiley
DOI: https://doi.org/10.1111/jth.13998
Usage rights: Creative Commons: Attribution 4.0
Please cite the published version
https://e-space.mmu.ac.uk
ORIGINAL ARTICLE
The chaperone protein HSP47: a platelet collagen binding
protein that contributes to thrombosis and hemostasis
P . SAS IKUMAR,* K . S . ALOUDA,* W. J . KA ISER ,* L . M. HOLBROOK,* N . KR IEK ,* A . J . UNSWORTH,*
A . P . BYE ,* T . SAGE ,* R . USH IODA,† K . NAGATA ,† R . W. FARNDALE‡ and J . M. G IBB INS*
*Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, UK; †Laboratory of
Molecular and Cellular Biology, Faculty of Life Sciences, Kyoto Sangyo University, Kyoto, Japan; and ‡Department of Biochemistry,
University of Cambridge, Cambridge, UK
To cite this article: Sasikumar P, AlOuda KS, Kaiser WJ, Holbrook LM, Kriek N, Unsworth AJ, Bye AP, Sage T, Ushioda R, Nagata K, Farndale
RW, Gibbins JM. The chaperone protein HSP47: a platelet collagen binding protein that contributes to thrombosis and hemostasis. J Thromb
Haemost 2018; 16: 946–59.
Essentials
• Heat shock protein 47 (HSP47), a collagen specific
chaperone is present on the platelet surface.
• Collagen mediated platelet function was reduced follow-
ing blockade or deletion of HSP47.
• GPVI receptor regulated signalling was reduced in
HSP47 deficient platelets.
• Platelet HSP47 tethers to exposed collagen thus modu-
lating thrombosis and hemostasis.
Summary. Objective: Heat shock protein 47 (HSP47) is an
intracellular chaperone protein that is vital for collagen
biosynthesis in collagen secreting cells. This protein has
also been shown to be present on the surface of platelets.
Given the importance of collagen and its interactions with
platelets in triggering hemostasis and thrombosis, in this
study we sought to characterize the role of HSP47 in these
cells. Methods and Results: The deletion of HSP47 in
mouse platelets or its inhibition in human platelets
reduced their function in response to collagen and the
GPVI agonist (CRP-XL), but responses to thrombin were
unaltered. In the absence of functional HSP47, the interac-
tion of collagen with platelets was reduced, and this was
associated with reduced GPVI-collagen binding, signalling
and platelet activation. Thrombus formation on collagen,
under arterial flow conditions, was also decreased
following the inhibition or deletion of HSP47, in the pres-
ence or absence of eptifibatide, consistent with a role for
HSP47 in enhancing platelet adhesion to collagen. Platelet
adhesion under flow to von Willebrand factor was unal-
tered following HSP47 inhibition. Laser-induced thrombo-
sis in cremaster muscle arterioles was reduced and
bleeding time was prolonged in HSP47-deficient mice or
following inhibition of HSP47. Conclusions: Our study
demonstrates the presence of HSP47 on the platelet sur-
face, where it interacts with collagen, stabilizes platelet
adhesion and increases collagen-mediated signalling and
therefore thrombus formation and hemostasis.
Keywords: chaperone; hemostasis; HSP47; platelets;
thrombosis.
Introduction
Heat shock protein 47 (HSP47) is a 400 amino acid resi-
due glycoprotein that is predominantly localized within
the secretory system of collagen-producing cells [1]. Here
it functions as a chaperone for newly synthesized procol-
lagens, stabilizing the triple helical structures that procol-
lagen trimers adopt [2,3]. Transgenic mice that lack both
alleles of the HSP47 gene (serpinH1) die in utero with the
appearance of abnormally deposited collagen basement
membranes. Because abnormal collagen synthesis under-
pins a host of fibrotic diseases, such as liver sclerosis or
pulmonary fibrosis, HSP47 is of interest as a potential
therapeutic target for such disorders [4].
Despite its well-characterized role as an intracellular
collagen chaperone, HSP47 was originally discovered on
the surface of mouse embryo parietal endoderm cells [5].
On these cells it was suspected to function as a receptor
for extracellular collagens, because it binds to native col-
lagen type IV and gelatin in vitro. Human oral squamous
carcinoma cells and chondrocytic cell lines were also
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reported to expose HSP47 on their surfaces [6,7]. All
three cell types synthesize collagen, so it is unclear
whether the role of HSP47 on the plasma membrane was
secondary to its chaperone activity.
We have previously reported that the peripheral mem-
brane fraction isolated from human platelets contained
HSP47 [8]. Platelets are anucleate, non-collagen produc-
ing cells that lack the classical ER system. However, they
interact with exposed collagen at sites of vessel wall injury
to form thrombi and plug the wound, thus preventing
blood loss. Our observation that HSP47 is exposed on
the platelet surface led to the hypothesis that HSP47 may
itself influence the interaction of platelets with collagen
following vessel injury.
In this study, we report that platelet HSP47 strengthens
platelet interactions with collagen in the formation of
thrombi and hemostasis, revealing a fundamental new
mechanism for chaperone protein function in the extracel-
lular regulation of cellular function.
Materials and methods
Ethics statement
Human blood collection was performed with approval
from the University of Reading Local Ethics Review
Panel. Experiments involving the use of animals (mice)
were performed in accordance with a licence from the
UK Home Office.
Immunofluorescence microscopy
Primary mouse megakaryocytes were isolated from
C57Bl/6 mice femur bone marrow as described previously
[9]. Fixed, non-permeabilized primary megakaryocytes
were stained with monoclonal rabbit anti-HSP47
(EPR4217, Abcam, Cambridge, UK) or control IgG,
then immunodetected with Alexa fluor 488 labelled anti-
rabbit antibodies and co-stained with Alexa 647 labeled
GPIb. The images were visualized by epi-fluorescence
microscopy (Leica Zeiss, Cambridge, UK, 1009 oil
immersion).
Cell surface biotinylation of HSP47
Cell surface biotinylation was performed as described pre-
viously [9]. The presence of HSP47 was analyzed by
immunoblotting and detected with anti-HSP47 (mouse
anti-HSP47, clone M16.10A1, Stressgen Biotechnologies,
Victoria, BC, Canada; 1:500), and the immunoblots were
re-probed using streptavidin-HRP to reveal total cell-sur-
face biotinylation and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) antibody (Abcam) as a negative
control for cytosolic proteins.
Collagen sepharose affinity chromatography
A total of 100 lg mL1 collagen type I or bovine serum
albumin (BSA) (protease free) was coupled to cyanogen bro-
mide-activated sepharose 4B (Sigma, Dorset, UK) as per the
manufacturer’s instructions. Washed platelets (4 9 108 cells)
were incubated with either small molecule inhibitor of
HSP47 (SMIH, compound IV, was identified from a large-
scale screen of compounds that interfered with HSP47 inter-
action with collagen and prevents its fibrillogenesis [10];
Maybridge, RH00007SC, 20 lM, Thermo fisher scientific,
Leicestershire, UK), vehicle (0.1% dimethylsulfoxide
[DMSO]) or inhibitory rabbit polyclonal anti-HSP47 (anti-
HSP47; the antibody was raised against synthetic peptide
corresponding to the collagen binding site [amino acid resi-
dues 406–417] of human HSP47 [lyophilized-azide free]; Life
Span Biosciences, Nottingham, UK), control rabbit IgG for
2 min at 37 °C and lysed with 2% (v/v) Nonidet P40 buffer
with protease inhibitors. Either collagen or BSA-sepharose
were added and rotated for 1 h at 4 °C. Following centrifu-
gation, pellets were re-suspended in reducing Laemmli buf-
fer. Protein samples were assessed by immunoblot analysis
using mouse HSP47 and GPVI antibodies (anti-human
GPVI [AF3627]). Cy2 anti-sheep IgG and Cy5 donkey anti-
mouse IgG (1:1000) were used for the detection of protein
bands using Typhoon Trio Fluorescence Imager (GE
Healthcare, Buckinghamshire, UK).
Preparation of washed human platelets, aggregation studies,
ATP secretion and calcium measurement
Human blood was obtained from healthy, drug-free vol-
unteers into 4% (w/v) sodium citrate and washed platelets
were isolated as described previously [11]. Using an opti-
cal aggregometer, washed human platelets (4 9 108
platelets mL1) were incubated with rabbit polyclonal
function blocking anti-HSP47 (anti-HSP47) or the rabbit
IgG at 37 °C for 2 min, followed by stimulation with col-
lagen (collagen type I fibres) (Nycomed, Munich, Ger-
many), CRP-XL and thrombin whilst stirring, and
aggregation traces were recorded.
Calcium measurement was performed as described pre-
viously [11]. Fura-2 loaded platelets were incubated with
anti-HSP47 or control IgG for 2 min at 37 °C prior to
addition of agonists. ATP secretion assays were per-
formed using luciferin-luciferase luminescence substrate as
described previously [11]. Platelets (4 9 108cells mL1)
were pre-incubated with luciferase prior to the addition of
anti-HSP47 or control IgG.
Generation of HSP47 conditional knockout mice
Mice homozygous for the HSP47 floxed allele (loxP sites
flanking exon 6) on a C57BL/6 background were generated
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as previously reported [12]. Mice lacking HSP47 in platelets
(Pf4-Cre; HSP47flox/flox) were generated by crossing HSP47
floxed mice with Pf4-Cre mice (Jackson Laboratories, Bar
Harbor, ME, USA) expressing Cre recombinase under con-
trol of the Pf4 promoter [13].
Preparation of washed mouse platelets, immunoblot
analysis, aggregation studies, receptor expression studies
and signaling studies
Mouse blood was collected by cardiac puncture and
washed platelets prepared as described previously [11].
Mouse platelet protein lysates were assessed by immuno-
blot analysis using rabbit anti-HSP47 antibody. Blots
were re-probed with anti-actin (C-11, Santa Cruz, Heidel-
burg, Germany) to control for protein loading levels. For
aggregation studies, washed mouse platelets (2 9 108
cells mL1) were stimulated with collagen and aggrega-
tion traces recorded. Whole mouse blood flow cytometry
studies were performed [14] to measure receptor expres-
sion levels on platelets using fluorescein isothiocyanate
(FITC)-conjugated antibodies for GPVI, integrin aIIbb3,
integrin a2b1 and GPIba (Emfret Analytics, Eibelstadt,
Germany). Signaling studies experiments were performed
as described previously [15]. Mouse platelets (4 9 108
cells mL1, HSP47flox/flox or Pf4-Cre; HSP47flox/flox) were
either untreated or stimulated with 1 lg mL1 CRP-XL
for 90 s at 37 °C, after which reducing SDS-PAGE sam-
ple buffer was added to stop the reaction. Immunoblot-
ting and band intensity analysis was performed as
described previously [15].
In vitro thrombus formation
Vena8 Biochips (Dublin, Ireland) were coated with colla-
gen (400 lg mL1) or von Willebrand factor (VWF)
(400 lg mL1) in Tyrodes-HEPES buffer overnight at
4 °C then blocked for 1 h with 1% (w/v) BSA. DiOC6
(0.87 lM DiOC6, 0.05% ethanol) labeled citrated mouse
blood was perfused over collagen-coated surface at a
shear rate of 1000 s1 for 10 min. Thrombi were visual-
ized using a Nikon eclipse (TE2000-U) inverted micro-
scope (Nikon Instruments, Surrey, UK) (N PLANL 10 x
objective) and analyzed using Slidebook 5.5.
For experiments using SMIH and inhibitory anti-
HSP47, fluorescently labeled human blood was incubated
with either SMIH or vehicle control (0.1% [v/v] DMSO)
or inhibitory anti-HSP47 or control IgG for 2 min at
37 °C. Blood was then perfused through glass capillary
slides (Camlab, Cambridge, UK) coated with collagen or
VWF (400 lg mL1) at a shear rate of 1000 s1 for
8 min. Thrombi were visualized using a Leica DMIRE2
inverted confocal microscope (20x/0.4) and analyzed
using TCS SP2 software (Leica, Mayfair, London, UK).
To study single platelet adhesion to collagen, blood
was pre-incubated for 2 min with eptifibatide (4 lM
eptifibatide; Fluorochem, Derbyshire, UK) prior to addi-
tion of HSP47 inhibitor (20 lM SMIH) or vehicle control,
or rabbit polyclonal anti-HSP47 or control IgG was per-
fused over collagen-coated glass capillary slides for 8 min.
Each slide was flushed with TBS/1% (v/v) NP40 buffer
and eluted. Platelet adhesion was measured either from
fluorescence intensity (Fiji, Image J, https://imagej.nih.
gov/ij/) or by protein estimation using BCA protein assay
(Pierce, Paisley, UK).
Laser injury of mouse microvessels and tail bleeding assay
In vivo analysis of thrombosis using a laser injury model
and tail bleeding assays were performed as described pre-
viously [11,16,17]. For experiments with HSP47 inhibitor,
SMIH (achieved a concentration in the blood of
approximately 20 lM) or vehicle control (0.1% [v/v]
DMSO) was infused into the mouse (C57Bl/6) circulation
5 min prior to laser injury or removal of tail tip. For the
thrombosis assay, GPIb subunit antibody was used for
in vivo platelet labelling (X488, Emfret Analytics). The
same procedure was used when thrombosis and tail bleed-
ing assays were performed for Pf4-Cre; HSP47flox/flox and
HSP47flox/flox.
Statistics
For two-group comparisons, Student’s t-test was used; P
values of < 0.05 were considered statistically significant
(n = 3 or more). Normalized data were subjected to statis-
tical analysis prior to normalization. Two-way ANOVA was
used for in vitro thrombus formation assay (GraphPad
Software, San Diego, CA, USA). The non-parametric
Mann–Whitney test was used to analyze non-normally-
distributed data (tail bleeding assay).
Results
Platelet-derived HSP47 is expressed constitutively on the
platelet surface and has megakaryocytic origins
Previous proteomics studies demonstrated the presence of
HSP47 in the peripheral membrane fraction of human pla-
telets [8,18]. Further flow cytometric analysis of washed
platelets (Figure S1Ai, Aii, Aiii, Aiv) and whole blood
analysis (data not shown) confirmed that resting human
platelets, which do not possess P-selectin on the cell sur-
face, display detectable levels of HSP47 immunoreactivity
on their surface. Being anucleate, platelet protein content is
derived almost exclusively from the progenitor megakary-
ocyte during megakaryopoiesis. Consistent with this, pri-
mary mouse megakaryocytes exhibited detectable levels of
HSP47 immunoreactivity on their surface membrane
(Fig. 1A). Further to this, to confidently establish the pres-
ence of HSP47 on the outer leaflet of the platelet plasma
membrane we carried out cell surface biotinylation and
© 2018 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
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purification of biotinylated human platelet proteins. Immu-
noblot analysis of isolated biotinylated surface proteins of
resting and CRP-XL (crosslinked collagen-related peptide)
stimulated human platelets revealed HSP47 to be constitu-
tively present on the platelet plasma membrane (Fig. 1Bi).
Figure 1(Bii) confirms that a range of membrane proteins
were biotinylated and revealed differential biotin labeling
between resting and stimulated human platelets, consistent
with the known upregulation of proteins on the platelet
surface upon activation. However, although by flow cytom-
etry an increase in cell surface HSP47 can be detected [8],
an increase in biotinylated proteins from CRP-XL-acti-
vated human platelets was not observed. This could be a
result of the biotinylation reagent gaining access to the
HSP47 in the open canicular system in addition to the pla-
telet surface. HSP47 in the open canicular system may rep-
resent the origins of increased surface levels upon
activation. The cytosolic protein GAPDH was used as a
control to confirm that biotinylation of proteins was con-
fined to the platelet surface (Figure 1Biii).
Platelet-derived HSP47 associates with collagen fibrils and
modulates GPVI adhesion to collagen
Given the importance of collagen in the initiation of plate-
let function, we asked whether platelet HSP47 interacts
with collagen. Platelet HSP47–collagen interaction was
investigated by means of collagen sepharose affinity chro-
matography. Immunoblot analysis revealed that platelet
HSP47 present in the cell lysates bound to collagen sephar-
ose beads with only limited interaction with BSA-coupled
beads. The level of HSP47 binding was reduced to back-
ground binding levels (equivalent to BSA–sepharose bind-
ing) in the presence of the small molecule inhibitor of
HSP47 (SMIH; Fig. 2Ai, Aii). Similarly, we studied plate-
let HSP47–collagen sepharose interaction in the presence
of inhibitory anti-HSP47. Immunoblot analysis showed
that HSP47 protein bound to collagen sepharose was
reduced (Fig. 2Bi, Bii). To determine whether platelet
HSP47 influences platelet interactions with collagen, we
investigated whether GPVI binding to collagen is regulated
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Fig. 1. HSP47 is present on the surface of platelet progenitor primary megakaryocytes and platelets. The presence of HSP47 on the surface of
primary megakaryocytes isolated from mouse bone marrow was demonstrated using epi-fluorescence microscopy under non-permeabilizing con-
ditions using rabbit monoclonal anti-HSP47 antibody. (A) Representative images for HSP47 (green), GPIb (red) and DAPI (blue). (B) The
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in the presence of HSP47 inhibitors. Immunoblot analysis
revealed that GPVI bound to collagen sepharose beads is
reduced in the presence of both HSP47 inhibitors (SMIH
and inhibitory anti-HSP47; Fig. 2Ci, Cii).
Flow cytometry analysis was employed to determine
whether HSP47 influences the ability of platelets to bind
to collagen. Binding of FITC-labeled collagen to human
platelets is reduced in the presence of small molecule inhi-
bitor (20 lM) or inhibitory HSP47 antibody
(10 lg mL1). There was no additional reduction in
FITC-labeled collagen binding to platelets in the presence
of both SMIH and inhibitory anti-HSP47 (Figure S1B).
Furthermore, on resting platelets the surface expression
of the receptors GPVI, integrin a2, integrin b3 and GPIb
in the presence of SMIH or inhibitory anti-HSP47 or in
combination was unaltered (Figure S1C, D, E, F).
Targeting surface-exposed HSP47 with antibodies attenuates
collagen-induced human platelet aggregation
We have demonstrated previously that the HSP47 inhibi-
tor SMIH (previously referred to as inhibitor of HSP47
[IOH] [8]) reduced platelet aggregation, particularly in
response to collagen. Because we cannot exclude that the
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small molecule inhibitor could gain access to intracellular
HSP47, here surface-expressed HSP47 was targeted using
a function blocking rabbit anti-HSP47 polyclonal anti-
body (Anti-HSP47). Full platelet aggregation, stimulated
with 1 lg mL1 collagen type I fibrils, was prevented
completely with 1 lg mL1 anti-HSP47 (Fig. 3Ai, Aii).
Higher concentrations of collagen (3 lg mL1) partially
overcame the inhibition (Fig. 3Bi, Bii). Low levels of inhi-
bition were observed when platelets were incubated with
10 lg mL1 anti-HSP47 and then stimulated with
0.3 lg mL1 CRP-XL (Fig. 3Ci, Cii). Thrombin (0.05
U mL1)-stimulated aggregation was unaffected in the
presence of inhibitory antibody (Fig. 3Di, Dii). Aggrega-
tion upon stimulation with convulxin, which potently
stimulates GPVI, was not reduced in the presence of anti-
HSP47 (Figure S2A, Aii), indicating that HSP47 func-
tions exclusively through a collagen (or collagen like, in
the case of CRP-XL) mediated response. To explore the
specificity of action for HSP47 in platelets, we investi-
gated the effect of HSP47 on aggregation responses to a
range of concentrations of collagen, CRP-XL or throm-
bin using a 96-well plate-based aggregation assay. At a
concentration of collagen (3 lg mL1) and CRP-XL
(0.3 lg mL1) that elicited comparable kinetics and
extent of aggregation, a reduction in platelet aggregation
in the presence of anti-HSP47 (10 lg mL1 anti-HSP47,
the highest concentration of inhibitory antibody, was
selected to compare with inhibition observed with light
transmission aggregometry) was observed (Figure S2A,
B). In contrast, no reduction in aggregation was observed
at any concentration of thrombin tested (Figure S2C).
Platelet HSP47 modulates calcium mobilization and dense
granule secretion
Ca2+ mobilization plays a pivotal role in various aspects
of platelet functions, such as shape change and degranula-
tion; hence, we investigated the role of HSP47 in this pro-
cess. Ca2+ levels were measured following collagen
stimulation for 75 and 100 s, and were reduced signifi-
cantly by 69% and 70%, respectively, in comparison with
control IgG (Fig. 4A, B). A higher concentration of colla-
gen (10 lg mL1) was required to stimulate detectable
Ca2+ levels under non-stirring conditions, consistent with
the previous studies [18]. Similarly, when platelets were
stimulated with CRP-XL (0.3 lg mL1) in the presence
of anti-HSP47 a significant reduction of ~68% at 75 s
was observed; however, at a later time-point of 100 s the
reduction was partially overcome (Fig. 4C, D). It is inter-
esting to note that although collagen-mediated Ca2+
mobilization was inhibited, CRP-XL-mediated responses
were only delayed.
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Because calcium mobilization is known to modulate
dense granule secretion, ATP secretion was assessed in
the presence of inhibitory anti-HSP47. ATP secretion was
reduced by approximately 50% and 26% in the presence
of anti-HSP47 (10 lg mL1) compared with control IgG
in platelets activated with collagen (3 lg mL1) or CRP-
XL (0.3 lg mL1), respectively (Fig. 4E–H).
Characterization of Pf4-Cre; HSP47flox/flox mouse platelets
Mice lacking platelet HSP47 were generated using the
recombination strategy mediated by expression of Cre
recombinase in megakaryocytes. Generation of HSP47flox/
flox (control) and Pf4-Cre; HSP47flox/flox (mice lacking plate-
let HSP47) mice were confirmed by PCR analysis of genomic
DNA isolated from ear tissue samples (Fig. 5A). The
absence of platelet HSP47 in Pf4-Cre; HSP47flox/flox mice
was demonstrated by immunoblot analysis using rabbit anti-
HSP47 (Fig. 5B). A full uncropped representative blot
including HSP47flox/flox, Pf4-Cre; HSP47flox/flox, human and
C57BL/6 platelets probed with anti-HSP47 is shown in Fig-
ure S3(A). Expression levels of platelet receptors integrins
aIIbb3, a2b1, GPVI and GPIb (Fig. 5C) on HSP47
flox/flox and
Pf4-Cre; HSP47flox/flox platelets were found to be compara-
ble. Platelet counts were also analyzed and found to be unaf-
fected by HSP47 deletion (Figure S3B).
Mouse platelets lacking HSP47 exhibit reduced platelet
activation
Platelet aggregation assays were performed to investigate
the effect of deletion of HSP47 on platelet function.
Aggregation of washed platelets lacking HSP47 (Pf4-Cre;
HSP47flox/flox) was reduced by ~40% at a concentration of
0.5 lg mL1 collagen (Fig. 5D, E) compared with control
(HSP47flox/flox) mouse platelets. At a higher concentration
of collagen (1 lg mL1), the reduction was maintained
but was less pronounced at ~30% (Fig. 5F, G), consistent
with the ability of high agonist concentrations to over-
come inhibition of HSP47 in human platelets (Fig. 3G,
H). Following stimulation with CRP-XL, mouse platelets
lacking HSP47 showed reduced aggregation and fibrino-
gen binding compared with control mice (Figure S4Ai,
Aii, B). However, no reduction in fibrinogen binding was
observed upon thrombin stimulation of platelets lacking
HSP47 in comparison with control platelets (Figure S4B).
Collagen (10 µg/mL) Collagen (10 µg/mL)
10 µg/mL Anti HSP47
CRP-XL (0.3 µg/mL) CRP-XL (0.3 µg/mL)
Conrtrol lgGControl lgG
10 µg/mL Anti HSP47 10 µg/mL Anti HSP47
Control lgG
10 µg/mL Anti HSP47
400
300
200
100
100
80
60
40
20
0
100
80
60
40
20
0
75 100
Time (s)
**
 *
*
 *
 *
*
0
0 50 100
Time (s)
Control
lgG
5
10
µg/mL Anti 
HSP47
Time (min)
0 2
0
20
5 2
Lu
m
in
es
ce
nc
e
%
 A
TP
 s
ec
re
tio
n
0
Time (min)
10
µg/mL Anti 
HSP47
10 µg/mL
Anti HSP47
Control 
lgG
CRP-XL (0.3 µg/mL) CRP-XL (0.3 µg/mL)
Control
lgG
100
80
60
40
0
10 µg/mL
Anti HSP47
Control
lgG
20
100
80
60
40
%
 A
TP
 s
ec
re
tio
n
Lu
m
in
es
ce
nc
e
[C
a2
+ ] 
nM
[C
a2
+ ] 
nM
%
 M
ax
im
al
 c
al
ciu
m
m
o
bi
liz
at
io
n
%
 M
ax
im
al
 c
al
ciu
m
m
o
bi
liz
at
io
n
Collagen (3 µg/mL)
Time (s)
75 100
100
50
0.
3 
µg
/m
L C
RP
-X
L
10
 µg
/m
L c
olla
ge
n
100
Time (s)
0
0
600
500
400
300
200
Collagen (3 µg/mL)
Control lgG
A B C D
E F G H
Fig. 4. Inhibition of HSP47 function reduces calcium mobilization and ATP secretion. Calcium mobilization was measured by spectrofluorime-
try in Fura-2 AM loaded platelets at excitation at 340/380 nm and emission at 510 nm. Platelets preincubated with anti-HSP47 (10 lg mL1)
or control IgG (10 lg mL1) were stimulated with 10 lg mL1 of collagen (A, B) or 0.3 lg mL1 of CRP-XL (0.3 lg mL1) (C, D). The
traces shown are representative of four separate experiments. The maximal calcium level obtained with control IgG was taken as 100% and
data normalized to this value. The level of ATP secretion was measured using lumino-aggregometry following stimulation with 3 lg mL1 of
collagen (E, F) and 0.3 lg mL1 of CRP-XL (G, H). Traces shown here are representative of three separate experiments. Data represent
mean  SD (n = 3; Student’s t-test, *P < 0.05). ATP secretion obtained with control IgG was taken as 100% and data were normalized to this
value.
© 2018 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
Thrombosis and Haemostasis.
952 P. Sasikumar et al
To establish whether the effects of SMIH or anti-
HSP47 could be attributed specifically to actions on plate-
let HSP47, we investigated their actions on control and
HSP47-deficient platelets. Prior to this, the ability of
HSP47 inhibitors to modulate murine (C57BL/6) platelet
function was tested and they were found to reduce the
mouse platelet aggregation (Figure S5Ai, Aii). Neither
the small molecule inhibitor of HSP47 nor the inhibitory
anti-HSP47 antibodies displayed any inhibitory effect on
HSP47-deficient platelets, confirming the specificity of
SMIH or antibody-mediated effects (Figure S5Bi, Bii, Ci,
Cii).
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Fig. 5. HSP47-deficient platelets display diminished response to collagen or CRP-XL. Mice lacking platelet HSP47(Pf4-Cre; HSP47flox/flox) were
generated using the recombination strategy mediated by expression of Cre-recombinase in megakaryocytes. (A) PCR analysis of genomic DNA
from Pf4-Cre; HSP47flox/flox and HSP47flox/flox ear tissue samples. (B) Immunoblot analysis of mouse platelet lysates at concentration 4 9 108
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(P > 0.05). Washed platelets from HSP47flox/flox and Pf4-Cre; HSP47flox/flox mice were stimulated with 0.5 lg mL1 collagen (D, E) or
1.0 lg mL1 collagen (F, G). Cumulative data are presented as mean  SD (n = 4). 100% aggregation is defined as the level of aggregation
obtained with HSP47flox/flox (control) (Student’s t-test, **P < 0.01 and *P < 0.05).
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HSP47 plays a significant role in thrombus formation in vitro
To examine the role of HSP47 in platelet reactivity under
physiologically relevant conditions in the presence of
other plasma components and other blood cells, DiOC6-
labeled blood from mice lacking platelet HSP47 and con-
trol mice was perfused over collagen. Epifluorescence
microscopy images were analyzed by calculating the sum
intensity of fluorescence as a measure of thrombus forma-
tion. Figure 6(Ai) shows the representative fields of view.
The sum intensity of fluorescence of thrombi formed with
blood from Pf4-Cre; HSP47flox/flox mice was reduced by
~50% at 10 min (Fig. 6Aii) in comparison to HSP47flox/
flox mice. Similarly, DiOC6-labeled whole human blood
was perfused through collagen-coated capillaries in the
presence of HSP47 inhibitors. The volume of thrombi
formed in SMIH-treated blood was reduced by 32% com-
pared with vehicle-treated blood (Fig. 6Bi), and at a con-
centration of 5 lg mL1 of anti-HSP47 the mean
thrombus volume was reduced by 27% compared with
control IgG Fig. 6Bii).
HSP47 supports platelet adhesion to collagen independently
of GPIb
Platelet thrombus formation is defined by the deposition
of platelets on collagen, with subsequent activation leading
to recruitment of nearby platelets. Hence, it is the initial
monolayer of platelets that may be most likely to influence
the growth of the thrombus formation. Therefore, we
investigated whether HSP47 plays a role in platelet adhe-
sion to ascertain whether inhibition of HSP47 reduced the
size of thrombi by preventing initial platelet–collagen
interactions. In vitro thrombus formation assays were per-
formed in the presence and absence of the integrin aIIbb3
inhibitor eptifibatide (4 lM). Platelet accumulation in the
presence of eptifibatide (4 lM) prior to treatment with
20 lM SMIH or inhibitory antibody was reduced because
of the lack of platelet–platelet interactions. Figure 6(Ci)
shows representative fields of view from confocal micro-
scopy. The levels of platelets adhered to collagen were
reduced by 32% in the presence of 20 lM SMIH compared
with vehicle-treated blood (Fig. 6Cii) and by 54% in the
presence of anti-HSP47 (5 lg mL1) compared with con-
trol IgG (Fig. 6Ciii). These data suggest that HSP47 influ-
ences the adhesion of platelets to collagen and thereby
contributes to subsequent activation.
It is possible that HSP47 inhibitors prevented platelet–
collagen interactions via the VWF receptor GPIb. To test
this, eptifibatide-treated (4 lM) whole blood was perfused
over VWF-coated capillaries in the presence of anti-
HSP47 or control IgG (Fig. 6D). Platelet adhesion to
VWF, which was quantified from fluorescence intensity,
was unaltered by HSP47 inhibition.
HSP47 modulates GPVI signaling
To determine whether early signaling events following
GPVI ligation were altered, the phosphorylation of SYK
525/526 was analyzed in platelets lacking HSP47. Control
mouse platelets (HSP47flox/flox) stimulated with CRP-XL
(1 lg mL1) showed an increase in tyrosine 525/526
phosphorylation at 90 s. However, HSP47-deficient plate-
lets (Pf4-Cre; HSP47flox/flox) showed reduced phosphoryla-
tion of SYK 525/526, consistent with attenuated GPVI
signalling (Fig. 6Ei, Eii). Furthermore, levels of PKC sub-
strate phosphorylation on serine residues following CRP-
XL stimulation in Pf4-Cre; HSP47flox/flox platelets were
reduced compared with HSP47flox/flox (Figure S6Ai, Aii).
Inhibition or deletion of platelet HSP47 reduces laser-
induced thrombosis
For intravital microscopy in mouse cremaster muscle
arteriole experiments, laser injury was optimized to
expose the extracellular matrix (ECM). Collagen type IV
immunoreactivity was detectable within 10 s after laser
injury (Figure S6B).
Fig. 6. HSP47 supports the initial adhesion of platelets to collagen, thus enhancing GPVI signaling. Blood drawn from HSP47flox/flox and Pf4-
Cre; HSP47flox/flox mice labeled with DiOC6 was perfused over collagen-coated surfaces at a wall shear rate of 1000 s1 for 10 mins. (Ai) Rep-
resentative images are shown. Captured images of adherent thrombi were analyzed by calculating the sum intensity of fluorescence as a mea-
sure of thrombus formation. (Aii) Surface coverage at 10 min is presented as mean  SD (n = 3); P = 0.02 by two-way ANOVA. (Bi)
Anticoagulated human blood without eptifibatide was labeled with DiOC6 incubated with small molecule inhibitor of HSP47 (SMIH) or con-
trols (dimethylsulfoxide [DMSO]) at (1000 s-1) for 4 mins. Thrombus volume was measured by confocal microscopy following incubation of
blood with 5 lM, 10 lM and 20 lM SMIH (mean  SD, n = 6, *P < 0.05). (Bii) Thrombus volume was measured following incubation of
blood with function blocking anti-HSP47 or control IgG (mean  SD, n = 6, *P < 0.05). (Ci) Representative fields of thrombi formed under
similar conditions with SMIH (20 lM) or vehicle control treatment in the presence of eptifibatide (4 lM). (Cii) The levels of platelet adhesion
to collagen were measured by analysis of concentration of protein eluted from flow cells after perfusion (mean  SD, n = 5, *P < 0.05). (Ciii)
Platelet adhesion was measured after incubation of human blood with anti-HSP47 or control IgG in the presence of eptifibatide (mean  SD,
n = 3, *P < 0.05). (D) Platelet adhesion to von Willebrand factor (VWF) in the presence of eptifibatide (4 lM) under arterial flow conditions
using fluorescently labeled human blood in the presence or absence of anti-HSP47 (mean  SD, n = 3, P > 0.05). (Ei, Eii) Platelets from
HSP47flox/flox and Pf4-Cre; HSP47flox/flox mice were stimulated by the addition of 1 lg mL1 CRP-XL for 90 s. Immunoblot analysis was per-
formed to detect total Syk phosphorylation using a phosphospecific Syk (Tyr 525/526) antibody. Data represent mean SYK 525/526 band
intensity  SD (n = 3). Student’s t-test, **P < 0.01. The band intensity of actin and Syk was used to control for protein loading levels.
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Anesthetized male C57BL/6 mice were injected intra-
venously with either SMIH or vehicle control prior to
vessel wall injury. Time-resolved images were captured
using intensified intravital fluorescence microscopy. Mean
of maximum fluorescence (maximum platelet recruitment)
obtained from individual thrombi was reduced by 66% in
the presence of SMIH compared with vehicle control in
mice (Fig. 7Ai, Aii). Thrombosis upon laser injury was
also assessed in mice lacking HSP47. Mean of maximum
fluorescence (maximum platelet recruitment) obtained
from individual thrombi was reduced by 54% in Pf4-Cre;
HSP47flox/flox mice compared with HSP47flox/flox mice
(Fig. 7Bi, Bii, Biii). The initial kinetics (up to 45s) of
thrombus formation (phase I in Fig. 7Bii) were unaltered
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in the absence of HSP47, consistent with no involvement
of HSP47 in GPIb-dependent platelet capture (Fig. 6D).
The following growth phase of thrombus formation
(phase II in Fig. 7Bii) was reduced. Beyond approxi-
mately 100 s the kinetics of thrombus decline were similar
(phase III in Fig. 7Bii).
Lack of HSP47 extends mouse bleeding times
Because HSP47 plays an important role in thrombosis, dis-
ruption of platelet function may be expected to compromise
hemostasis. Five minutes after intravenous injection of
SMIH or vehicle to C57Bl/6 mice, tail biopsies were per-
formed and bleeding time was recorded. Mean tail bleeding
time increased by 31% (117  13 s vs. 192  30 s,
Fig. 8A). Consistent with the inhibition of HSP47, platelet-
specific HSP47-deficient mice had prolonged tail bleeding
times by approximately 1.8-fold in comparison with control
mice (265.3  106.9 s [platelet HSP47-deficient mice] vs.
146.5  58.99 s [control mice], Fig. 8B).
Discussion
Platelet adhesion and activation on collagen involves platelet
surface receptors, including GPIb-V-IX, GPVI and integrin
a2b1, functioning in a coordinated and potentially synergistic
manner [19,20]. Although HSP47 is primarily known for its
function as a collagen binding protein, it also shares
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Fig. 7. Absence or inhibition of HSP47 reduces thrombosis. (Ai) Thrombosis was measured following laser injury of cremaster muscle arteri-
oles by intravital microscopy. C57BL/6 mice were administered small molecule inhibitor of HSP47 (SMIH) or vehicle control via cannula prior
to injury. Platelets were labeled by infusion of Alexa Fluor 488-conjugated anti-GPIb antibody. Representative images of thrombi from vehicle
control and SMIH (20 lM in blood volume) following injury are shown. (Aii) Data represent mean maximum fluorescence, n = 27 thrombi
from each group, P = 0.012. (Bi) Intravital microscopy was performed on Pf4-Cre; HSP47flox/flox and HSP47flox/flox mice. (Bii) Mean of maxi-
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mice) (Student’s t-test, P = 0.031). Images are 960 magnification. (Biii) The kinetics of the platelet accumulation during thrombus growth was
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platelets in arbitrary units is presented as a function of time. [Color figure can be viewed at wileyonlinelibrary.com]
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sequence homology with the serine protease inhibitor (ser-
pin) family. However, sequence differences in the active site
render the protein inactive as a serpin [21], as confirmed in
protease inhibition studies with purified recombinant mouse
HSP47 [22]. Using a range of in vitro and in vivo assays of
platelet function, HSP47-deficient mouse platelets and selec-
tive inhibitors, we provide compelling evidence for an
important extracellular role for this protein, predominantly
in collagen-mediated platelet function.
In this study, platelet-derived HSP47 was confirmed to
bind to mature collagen type I fibrils, a collagen type pre-
sent within the arterial wall [23], in accordance with the
previous reports that HSP47 binds to collagen types I to
V [24]. A study by Nakai et al. [25] has shown the inabil-
ity of HSP47 to interact with other constituents of the
extracellular matrix such as laminin or fibronectin [25].
Therefore, the actions of HSP47 in platelets are likely to
be mediated through interactions with the collagenous
component of the ECM.
Blockade of platelet HSP47 or its deletion in mice led to
a reduction in platelet responses to collagen and CRP-XL.
Furthermore, in vivo studies using a laser injury model of
cremaster muscle arterioles revealed an important role for
HSP47 in thrombus formation. The initial phases of
thrombus formation were found to be unaltered in the
absence (or inhibition) of HSP47. The early phase of pla-
telet entrapment at sites of injury is indirect and depen-
dent on GPIb–VWF interactions. The interaction was
found not to be regulated by HSP47, and therefore the ini-
tial phases of thrombus formation would be expected to
be unchanged in the absence of HSP47 activity. The rapid
thrombus propagation and growth that follows initial
entrapment, a response that is dependent on direct interac-
tions of collagens with GPVI and integrin a2b1, was
reduced substantially in the absence of HSP47 activity.
Hence, we propose that HSP47 strengthens and enhances
platelet–collagen interactions following the initial GPIb-
dependent platelet entrapment.
It is currently unclear how HSP47 exerts this effect,
whether through modulation of ligand structure, or
indeed because it functions as an adhesion protein to
enhance platelet–collagen interactions. Recent evidence
indicates that GPVI can also bind to fibrin, hence we
investigated whether HSP47 could alter platelet adhesion
and spreading to fibrin [26]. Deletion of HSP47 does not
alter the platelet adhesion to fibrin (Figure S6Ci, Cii).
Although the inhibition or deletion of HSP47 reduced
thrombosis in mice, bleeding was also extended, indicat-
ing a fundamental role for this extracellular chaperone
protein in thrombosis.
The escape of normally endoplasmic reticulum-resident
proteins to the extracellular environment is shared in pla-
telets with thiol isomerases, a family of oxidoreductases
that contribute to the folding of nascent proteins. These
proteins are also implicated in the modulation of
hemostasis and thrombosis [17,27].The discovery that
extracellular HSP47 modulates platelet responses selec-
tively to collagen suggests that the ability of chaperone
proteins to function in the extracellular environment may
represent an hitherto unrecognized paradigm where such
proteins may continue to ‘chaperone’ protein structure
and function outside of the cellular secretory pathway.
This may be important in a number of other (patho)
physiological circumstances.
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